BPN 14770

Drug Profile

BPN 14770

Alternative Names: BPN-14770

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Tetra Discovery Partners
  • Class Antidementias
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Cognition disorders

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 20 Jan 2017 Tetra Discovery Partners plans a phase I trial in Healthy volunteers in USA (NCT03030105)
  • 19 Dec 2016 Adverse events data from two phase I trials in Healthy volunteers released by Tetra Discovery Partners
  • 29 Nov 2016 Tetra Discovery Partners receives SBIR grant from National Institute on Aging for BPN 14770 development in Alzheimer's disease (In volunteers)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top